Literature DB >> 15498877

Place of newer quinolones and rifampicin in the treatment of Gram-positive bone and joint infections.

Frédéric Frippiat, Françoise Meunier, Geneviève Derue.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15498877     DOI： 10.1093/jac/dkh451

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  7 in total

1.  Influence of daily dosage and frequency of administration of rifampicin-levofloxacin therapy on tolerance and effectiveness in 154 patients treated for prosthetic joint infections.

Authors:  S Nguyen; O Robineau; M Titecat; N Blondiaux; M Valette; C Loiez; E Beltrand; H Migaud; E Senneville
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-05-19       Impact factor: 3.267

2.  In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.

Authors:  Olivier Grossi; Jocelyne Caillon; Cedric Arvieux; Cedric Jacqueline; Denis Bugnon; Gilles Potel; Antoine Hamel
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

3.  Antimicrobial effects of nanofiber poly(caprolactone) tissue scaffolds releasing rifampicin.

Authors:  Timothy T Ruckh; Rachael A Floreani; Derek A Carroll; Krasimira Mikhova; James D Bryers; Ketul C Popat
Journal:  J Mater Sci Mater Med       Date:  2012-03-10       Impact factor: 4.727

4.  Italian guidelines for the diagnosis and infectious disease management of osteomyelitis and prosthetic joint infections in adults.

Authors:  S Esposito; S Leone; M Bassetti; S Borrè; F Leoncini; E Meani; M Venditti; F Mazzotta
Journal:  Infection       Date:  2009-11-10       Impact factor: 7.455

Review 5.  Antimicrobial agents in orthopaedic surgery: Prophylaxis and treatment.

Authors:  Andrej Trampuz; Werner Zimmerli
Journal:  Drugs       Date:  2006       Impact factor: 11.431

6.  Efficacy of antibiotic treatment of implant-associated Staphylococcus aureus infections with moxifloxacin, flucloxacillin, rifampin, and combination therapy: an animal study.

Authors:  Felix Greimel; Christine Scheuerer; Andre Gessner; Michaela Simon; Thomas Kalteis; Joachim Grifka; Achim Benditz; Hans-Robert Springorum; Jens Schaumburger
Journal:  Drug Des Devel Ther       Date:  2017-06-14       Impact factor: 4.162

7.  Impact of rifampicin dose in bone and joint prosthetic device infections due to Staphylococcus spp: a retrospective single-center study in France.

Authors:  M Tonnelier; A Bouras; C Joseph; Y El Samad; B Brunschweiler; J-L Schmit; C Mabille; J-P Lanoix
Journal:  BMC Infect Dis       Date:  2021-02-12       Impact factor: 3.090
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.